According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Other equities analysts have also issued reports about the company. ValuEngine lowered Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. Mizuho restated a buy rating and set a $37.00 target price on shares of Revance Therapeutics in a research report on Wednesday, April 24th. Finally, HC Wainwright set a $55.00 target price on Acer Therapeutics and gave the stock a buy rating in a research report on Tuesday, May 28th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $18.91.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.13) by $0.05. The company had revenue of $11.67 million during the quarter, compared to analyst estimates of $12.78 million. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. Equities analysts forecast that Adamas Pharmaceuticals will post -3.77 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Arbitrage SA acquired a new position in shares of Adamas Pharmaceuticals in the 1st quarter valued at approximately $33,000. PNC Financial Services Group Inc. acquired a new position in shares of Adamas Pharmaceuticals in the 1st quarter valued at approximately $43,000. Advisor Group Inc. grew its position in shares of Adamas Pharmaceuticals by 252.0% in the 4th quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 4,510 shares during the period. Barclays PLC grew its position in shares of Adamas Pharmaceuticals by 87.6% in the 4th quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock valued at $148,000 after purchasing an additional 8,118 shares during the period. Finally, Creative Planning acquired a new position in shares of Adamas Pharmaceuticals in the 1st quarter valued at approximately $144,000. Institutional investors and hedge funds own 76.68% of the company’s stock.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Further Reading: Price-Sales Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.